Oral Presentation Details
A Randomized Clinical Trial of Three Doses of a Long-Acting Oral Direct Factor Xa Inhibitor Betrixaban in Patients With Atrial Fibrillation (Presentation #3015-12)
Presenter: Dr. Michael D. Ezekowitz
Session: Late-Breaking Clinical Trials II: Cardiac Arrhythmias
Date: Monday, March 15, 8:51-9:03 a.m. ET
Location: Georgia World Congress Center, Murphy Ballroom
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All